In the ever-evolving landscape of global commerce, a silent but escalating battle rages on. The protagonists? Brands, consumers, and regulatory authorities. Their adversary? An increasingly sophisticated network of counterfeiters, whose capabilities have surged with the aid of advanced technologies. This conflict has spread far beyond the realms of luxury fashion, electronics, pharmaceuticals, and a myriad of consumer goods. As we navigate through 2024, it’s evident that the counterfeit market has not only grown in volume but in the finesse of its deceptions.

The Rise of Sophistication

Gone are the days when counterfeit goods were easily spotted, relegated to the shady corners of the internet or the dubious street vendor. Today’s fakes are a different breed altogether, crafted with such precision that they blur the lines between authenticity and imitation. This leap in quality owes much to advancements in technology and manufacturing techniques, which have armed counterfeiters with the tools to mimic legitimate products with alarming accuracy.

The Twin Pillars of Counterfeit Evolution

What has enabled counterfeiters to make such a significant advance? The root of this progression can be traced back to the exploitation of technology and the emergence of artificial intelligence (AI). Firstly, there’s the issue of access to specialized production tools, such as machines for making pills, which were previously available only to verified entities but have now been spotted for sale to the general public on platforms like eBay. Additionally, the illicit access to or mishandling of original print files facilitates the production of highly convincing fakes. Secondly, AI has emerged as a groundbreaking tool in the arsenal of counterfeiters, allowing them to create imitations with an accuracy that was previously deemed impossible. This has led to a remarkable increase in the quality of counterfeit goods, highlighting a quiet yet rapid evolution in the methods of counterfeiting.

Impact on Brands and Consumers

This surge in counterfeit sophistication poses dire consequences for brands and consumers alike. For businesses, the infiltration of fakes not only erodes brand integrity but translates into significant financial hemorrhage. Consumers, on the other hand, face risks that transcend monetary loss. Counterfeit pharmaceuticals may endanger health, fake electronics could flout safety standards, and the list goes on. The stakes are undeniably high, underscoring the urgent need for a robust response.

The Future Battlefront: Anticipating Trends and Preparing Defenses

As counterfeiters grow more adept, the onus is on authorities and industries to stay one step ahead. This means not allowing the technological gap to widen but instead investing in the latest defensive technologies. The battle against counterfeits is not lost; it simply demands a shift in strategy. By leveraging AI and other forward-thinking technologies, we can build a more resilient defense against the counterfeit onslaught.

A Call to Arms: Leveraging AI for Defense

In the face of such sophisticated threats, mere vigilance is insufficient. What’s required is a comprehensive strategy that not only anticipates future trends but actively counters them. AI, with its vast potential for detecting and distinguishing between genuine and counterfeit products, stands at the forefront of this battle. It’s not just about fighting back; it’s about outsmarting the counterfeiters at their own game.

The rise of counterfeit sophistication in 2024 is a call to action for brands, consumers, and authorities alike. While the challenge is formidable, it is not insurmountable. By embracing AI and advanced technologies like the TrueMed Digital Forensic Lab, we can turn the tide against counterfeiters, safeguarding both brand integrity and consumer safety. The future of this battle will be shaped by our willingness to invest in and adopt innovative solutions. The time to act is now; the cost of inaction is too great.

The global health landscape is increasingly challenged by the rise of counterfeit medications. Far from being just a financial problem, these illicit drugs pose significant health hazards and broadly destabilize the foundation of healthcare systems internationally.

Understanding Counterfeit Medications

Counterfeit medications are unauthorized replicas of genuine drugs, which can include not just incorrect or harmful ingredients but also simply just water, especially in vials. These substances lack the therapeutic efficacy of their legitimate counterparts, exacerbating health conditions by failing to provide appropriate treatment. Moreover, this exposes patients to potentially toxic substances, further endangering their health and safety. The global market for counterfeit pharmaceuticals was estimated to be worth $200 billion annually, making it one of the most lucrative sectors of the global trade in illegally copied goods, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).

The World Health Organization (WHO) has identified that roughly 1 in 10 medical products in low- and middle-income countries is either substandard or falsified. These counterfeit products span a wide range of medical categories, including critical medications like anti-malarial and antibiotics. The WHO also reports that counterfeit medication is responsible for the deaths of an estimated 1 million people annually worldwide.

A Global Concern

Despite having one of the safest drug supplies in the world, even the United States is not immune to the counterfeit drug issues. The FDA emphasizes that illegal online pharmaceutical sales are a primary conduit for counterfeit medicines entering the American market. The National Association of Boards of Pharmacy (NABP) reported that out of thousands of online pharmacies reviewed, over 95% do not comply with legal and safety standards, posing a significant risk for consumers seeking medication online. This digital loophole poses significant challenges to regulatory and enforcement agencies. The Centers for Disease Control and Prevention (CDC) has observed a concerning trend in drug overdose deaths linked to counterfeit pills. These counterfeit pills, often laced with potent substances like fentanyl, have contributed to a sharp rise in overdose fatalities.

Countries such as Brazil, Argentina, and Colombia have reported significant seizures of counterfeit drugs, highlighting the widespread nature of this problem. These illicit medications range from fake versions of popular painkillers to counterfeit treatments for life-threatening conditions like cancer and heart disease. The open borders and varied regulatory standards across South American countries facilitate the entry and distribution of counterfeit drugs, complicating efforts to curb their spread.

Asia faces a unique set of challenges in the fight against counterfeit medications, partly due to its vast size, population diversity, and disparities in healthcare infrastructure. Countries like China and India, with their large pharmaceutical industries, are both significant sources and victims of counterfeit drugs. These counterfeit medications not only undermine public health but also damage the reputation of legitimate manufacturers. The region has seen everything from counterfeit antivirals and antibiotics to fake vaccines, especially during the COVID-19 pandemic, which has exacerbated the problem. Efforts to tackle this issue in Asia include stricter regulatory measures, cross-border collaboration, and the adoption of advanced technologies for drug verification and tracking. However, the sheer scale of the counterfeit drug trade in Asia demands continuous and coordinated efforts at both national and international levels to protect consumers and ensure the safety of the pharmaceutical supply chain.

Europe also grapples with the complexities of counterfeit drugs, although the prevalence is lower compared to other regions, thanks to stringent regulatory frameworks and effective enforcement. However, the rise of online pharmacies has opened a new front in the fight against fake drugs, with European consumers at risk of purchasing counterfeit medications from illegitimate websites. The European Union has implemented several measures to safeguard the pharmaceutical supply chain, including the Falsified Medicines Directive (FMD) and the European Medicines Verification System (EMVS), which aims to ensure the authenticity of medicinal products. Despite these efforts, the problem persists, with incidents of counterfeit cancer medications, antibiotics, and erectile dysfunction pills being reported in various European countries. Collaboration between national regulatory agencies, healthcare providers, and the pharmaceutical industry is crucial to addressing the issue, along with continued public education on the risks of buying medicines from unverified sources.

A Beacon of Hope 

Combating counterfeit medications demands a multifaceted approach. Strengthening international cooperation, enhancing regulatory frameworks, and raising public awareness are critical steps. Technological innovations, including sophisticated drug authentication methods, can play a pivotal role in identifying and eliminating counterfeit drugs from the market.

The counterfeit medication crisis is a complex and pervasive challenge with far-reaching implications for global health. To effectively mitigate its impact, concerted efforts are required from governments, healthcare providers, regulatory agencies, and the public, alongside advanced technologies like the Digital Forensic Lab developed by TrueMed. TrueMed’s innovative AI-powered solutions play a crucial role in this battle, offering effective tools for detecting counterfeit medications. By uniting in this fight, leveraging both policy and technological advancements, we can strive to protect public health and maintain the integrity of the global pharmaceutical supply chain.

Sources:

World Health Organization: Substandard and falsified medical products https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products

U.S. Food and Drug Administration: Counterfeit Medicine https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine

Centers for Disease Control and Prevention: Drug Overdose Deaths with Evidence of Counterfeit Pill Use — United States, July 2019–December 2021 https://www.cdc.gov/mmwr/volumes/71/wr/mm7114a1.htm

UK Government: Counterfeit medicines: what pharmacists should know https://www.gov.uk/government/publications/counterfeit-medicines-what-pharmacists-should-know

[Helsinki, 06FEB2024] TrueMed, the leading provider of anti-counterfeiting technology solutions for pharmaceuticals, announces a strategic collaboration with an additional global leader in pharmaceuticals and healthcare. An additional top 10 pharmaceutical company has joined forces with TrueMed, reflecting a shared commitment to combat the surge of counterfeit and illicit medicines. Leveraging TrueMed’s Digital Forensic Lab and advanced AI technology, the collaboration is poised to make a meaningful impact on patient safety by effectively detecting and addressing counterfeit drugs.

TrueMed’s innovative AI platform, utilizing mobile phone cameras, artificial intelligence to reach high accuracy, and data analytics, is at the forefront of accurately identifying counterfeit pharmaceuticals, strengthening the pharmaceutical company’s capacity for investigation and response. This technology is integral to forensic analyses and seamlessly integrates with existing security processes, streamlining the fight against fake medications without necessitating costly manufacturing changes.

TrueMed was chosen as a partner for its expertise and commitment to the safety and integrity of medicines. This collaboration is centered on enhancing laboratory capabilities to efficiently identify and investigate counterfeit drugs. The partnership aims to guarantee the delivery of safe and authentic treatments, addressing a crucial need in healthcare for dependable and effective medication.

Jyrki Berg, CEO of TrueMed, remarked on the significance of this collaboration, noting, “Our strategic alliance with this pharmaceutical leader is a significant step towards directly addressing the challenge of counterfeit drugs. Through this partnership, we’re employing the latest technologies and drawing on deep industry expertise to significantly advance patient safety globally.”

This partnership reflects a shared goal in the pharmaceutical industry to innovate and improve patient care. It shows how AI is important in keeping healthcare safe and marks a significant step forward in working together to protect health worldwide.

For additional insights into TrueMed’s advanced AI-based anti-counterfeiting solutions, please visit www.truemedinc.com.

About TrueMed.  

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com

TrueMed enhances field investigations with advanced AI-powered counterfeit detection.   

[Helsinki, 10JAN2024] – TrueMed, the leading provider of anti-counterfeiting technology solutions, has announced its selection by a leading global pharmaceutical company to enhance the fight against counterfeit medications. This collaboration represents a significant commitment to ensuring the safety and integrity of its extensive product portfolio, reinforcing both companies’ dedication to patient safety and brand protection. 

The initiative comes in response to the increasing sophistication of counterfeit medications, which pose a risk to patient health and the overall trust in healthcare. By incorporating TrueMed’s advanced detection technologies, the pharmaceutical company aims to significantly improve the accuracy and efficiency of identifying fake drugs within the market. TrueMed’s system offers a substantial improvement over traditional detection methods, which often rely on manual inspection and can miss high-quality counterfeits. 

As part of this collaboration, field investigators will be equipped with TrueMed’s cutting-edge tools, enhancing their ability to identify and report counterfeit products. This technology reduces the need for extensive training and experience traditionally required for counterfeit detection, allowing for a more agile and effective response to the ever-evolving threat of fake medications. 

“The increase in counterfeiter sophistication demands a rigorous response, and we are committed to that challenge,” said Jyrki Berg, CEO of TrueMed. “Our digital laboratory’s technology provides timely and accurate detection, supporting the investigators in unprecedented ways. Our goal is to not just respond to counterfeiting trends but to actively define higher standards for product safety and authenticity.” 

TrueMed simplifies the field inspection process by allowing less skilled investigators to conduct effective work. The technology takes over complex identification tasks, enabling more widespread and cost-effective investigations without the need for extensive training or experience. This approach helps scale up operations efficiently, making field inspections more accessible. 

For more information about TrueMed’s advanced AI-counterfeit detection solutions, please visit www.truemedinc.com. 

About TrueMed.  
 
TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers. 

For more information, please visit truemedinc.com. 
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com 

[Helsinki, 13 DEC 2023] – TrueMed, the leading provider of anti-counterfeiting technology solutions, announces its selection by a top 10 global pharmaceutical company to enhance their counterfeit detection capabilities. This partnership marks a significant step in the digitalization and modernization of laboratory processes in the fight against counterfeit drugs.

“Counterfeiters are becoming more sophisticated, and we’re determined to outsmart them at every turn,” asserts Jyrki Berg, CEO of TrueMed. “Our lab’s advanced capabilities in delivering instant, accurate results are in line with the pharmaceutical company’s goals of innovation and proactive defense. We’re not just keeping pace with counterfeiters; we’re setting the pace, ensuring that patient safety and product authenticity remain uncompromised.”

Featuring AI and image analysis for instant product verification, the Digital Forensic Lab enables investigators to perform additional checks without physical shipping, avoiding extra logistical costs. Its ability to efficiently identify previously known counterfeit products minimizes the need for manual validations.

The Digital Forensic Lab’s complements the pharmaceutical company’s objective of employing cutting-edge tools to safeguard its products. By integrating this lab into their processes, the company is better equipped to handle the increasing complexity of counterfeit drug cases, ensuring that their response is not only swift but also deeply integrated into their broader operational and strategic framework.

The partnership between TrueMed’s Digital Forensic Lab and the pharmaceutical company not only signifies a milestone in enhancing drug authenticity and safety but also brings remarkable efficiency gains. By reducing each counterfeit analysis from 4 hours to just 15 minutes, an impressive 94%-time savings.

Jyrki Berg, CEO of TrueMed, remarks, “This partnership is transformative. By integrating our advanced forensic capabilities with strategic foresight, we’re disrupting the approach to counterfeit drug analysis, ushering in more secure and reliable pharmaceutical practices.”

For more information about TrueMed’s advanced AI-counterfeit detection solutions, please visit www.truemedinc.com.

About TrueMed.

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com

[Helsinki, 27NOV2023] – TrueMed, the leading provider of anti-counterfeiting technology solutions, is proud to launch its cutting-edge Digital Forensic Lab, a significant expansion in its suite of counterfeit detection solutions. This innovative solution delivers advanced digital forensic analysis, significantly accelerating the process of precise and thorough investigation in complex counterfeit cases. 

“As counterfeiters become more sophisticated in their methods, it’s imperative that our technology evolves at an even faster pace to detect them.” said Jyrki Berg, CEO of TrueMed  “By providing instant results and comprehensive case reporting, we empower laboratories and brand holders with unprecedented speed and accuracy in product verification.” 

The Digital Forensic Lab integrates image capture with AI and machine learning for instant product verification. The system also allows investigators to conduct further verifications without the need for physical shipping, thereby circumventing additional logistical and third-party expenses. A notable feature of the Digital Forensic Lab is its capability to efficiently manage and recognize previously identified counterfeit products, reducing the necessity for repeated validations.  

“Our Digital Forensic Lab eliminates the need for lengthy physical lab tests and manual reporting as all data is automatically centralized” added Jyrki. “This ensures that brand holders and investigators have real-time, actionable insights at their fingertips.” 

TrueMed’s Digital Forensic Lab, now available to healthcare organizations, pharmaceutical companies, and regulatory bodies, offers a reliable solution for identifying counterfeit products without needing a physical lab. This cost-effective tool complements existing labs, providing enhanced efficiency and savings while ensuring product authenticity and safety. 

For additional details please visit our website at https://truemedinc.com/digital-forensic-lab/ 

About TrueMed 

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com 

https://www.youtube.com/watch?v=IgxMzdsA4ek

Tech-Empowered Labs

Tired of the old-fashioned, time-consuming lab processes? Say hello to TrueMed, your gateway to the digital future of laboratory services.

Learn More

The pharmaceutical industry has been going through a seismic shift as digital pharmacies are changing how patients receive their medications. In an era where convenience is king, the ability to have prescriptions filled online and delivered straight to the doorstep is a welcome evolution for many. However, as with any significant change, this new model introduces complexities, and with each handoff from manufacturer to patient, risks arise. The solution, however, may lie in the sophisticated realm of artificial intelligence (AI), which holds promise for securing the pharmaceutical supply chain against counterfeits and contamination.

The Rise of Digital Pharmacies

Digital pharmacies have capitalized on the intersection of technological advancements and consumer demand for convenience. No longer do patients need to wait in line at the local drugstore; instead, they can have their prescriptions processed, filled, and delivered without leaving their homes. This service is particularly beneficial for the elderly, those with chronic conditions requiring regular medication, and people living in remote areas. Moreover, the integration of telehealth services has streamlined the process of obtaining prescriptions, further embedding digital pharmacies into the healthcare routine of millions.

Added Complexity Equals Added Risk

Each step in the delivery process adds layers of complexity that can increase the risk of counterfeit products infiltrating the supply chain. These risks aren’t just theoretical; they have real-world implications for patient safety. The World Health Organization (WHO) estimates that 1 in 10 medical products in low- and middle-income countries is substandard or falsified. This problem isn’t confined to developing nations; developed countries are also at risk, as their increasingly complex supply chains offer more opportunities for illicit activities.

Traditional security measures like serialization and secure packaging are crucial, but they may not be enough. For instance, a medication could be tampered with or stored improperly during transit, leading to reduced efficacy or, worse, harm to the patient. Additionally, the more intermediaries involved in the distribution process, the harder it is to track the origin and handling of medications, increasing the risk of counterfeit goods entering the market.

AI: The Guardian of the Supply Chain

The challenges of securing the supply chain might seem daunting, but AI presents a powerful tool to enhance protection against counterfeits. AI systems can be trained to scrutinize vast amounts of data to identify patterns and anomalies that would be invisible to human analysts. For instance, machine learning algorithms can monitor and analyze patterns across the supply chain to group identical counterfeits

Moreover, AI can improve the traceability of drugs by analyzing and managing serialization data, ensuring that each pill can be tracked back to its source. Image recognition technologies can inspect and verify medications and packaging at various points in the supply chain, flagging any discrepancies for further investigation.

These AI-driven systems can also be integrated with existing security measures to create a multi-layered defense strategy.

The expansion of digital pharmacies is a testament to the digital transformation of healthcare. Market statistics highlight not only the rapid adoption of digital pharmacy services but also the escalating complexity and associated risks within the pharmaceutical supply chain. As these trends continue, leveraging advanced technologies like AI for counterfeit detection becomes not just innovative but essential. AI is poised to be the linchpin in ensuring the safety and integrity of pharmaceuticals, providing reassurance that the convenience of home delivery does not come at the expense of quality or patient safety.

We had the privilege of sitting down with Tuomas Kannas, Co-Founder & Senior Vice President of TrueMed, who also represents the Finnish Anti-Counterfeiting Group (FACG) on the board of the Global Anti-Counterfeiting Group (GACG).

Tuomas, could you start by telling us a bit about what the GACG is and its primary objectives?

Tuomas Kannas: Certainly. The Global Anti-Counterfeiting Group, or GACG for short, is an international network of national and regional IP protection and enforcement organizations covering more than 50 countries. Our members consist of nonprofit associations of IP rights holders and their representatives. The primary objectives of GACG revolve around three key areas:

1. Coordinating International Activities: GACG’s goal is to align the efforts of its members, especially concerning interactions with international governmental organizations.
2. Producing Research and Reports: We are dedicated to generating comprehensive research and reports that shed light on the international dimensions of counterfeit trade, creating public awareness.
3. Exchanging Best Practices: GACG fosters the exchange of best practices among its members, aiding in the establishment of national and other anti-counterfeiting groups.

How does the GACG measure the success or impact of your anti-counterfeiting efforts?

Tuomas Kannas: We have several criteria to gauge the success or impact of our anti-counterfeiting initiatives:  The visibility of our joint campaigns, reports, and initiatives is a clear indicator of engagement and effectiveness.  Input from member organizations and external stakeholders provides insights into the effectiveness of our efforts. We also consider the influence and effect of legislative changes or reports in question as important metrics of success.

Over the years, how do you believe the landscape of counterfeiting and intellectual property rights enforcement has changed?

Tuomas Kannas: The landscape has certainly evolved. Priorities have shifted, and collaboration between public and private entities has become more robust and official. There’s also a heightened understanding of the complexity of counterfeiting issues across different countries and sectors of society.

Could you tell us how the Global Anti-Counterfeiting Group collaborates with other international organizations, national governments, and private corporations in its anti-counterfeiting initiatives?

Tuomas Kannas: GACG collaborates with various international organizations, national governments, and private corporations by sharing our expertise, providing consultation, and offering statements and recommendations for international initiatives and stakeholders.

Given the varying legal structures and enforcement capabilities among different countries, what strategies does your organization use to effectively enforce IPR internationally?

Tuomas Kannas: It’s important to clarify that GACG doesn’t enforce; rather, it’s the member organizations’ right holders and law enforcement agencies that carry out enforcement activities.

Looking forward, what emerging trends or potential challenges do you anticipate in the field of global anti-counterfeiting?

Tuomas Kannas: Counterfeiters are becoming more adept at creating sophisticated production, logistics, and sales capabilities. They quickly adapt to changes in demand, enforcement, and disruptions. Production is increasingly decentralized, happening in smaller and movable facilities, with a surge in digital sales platforms. In response, anti-counterfeiting efforts need to focus on consistent data, shared intelligence, stricter legislation, and coordinated operations both online and offline.

As a board member, what are your personal priorities or areas of focus for the group?

Tuomas Kannas: My personal priorities include fostering more coordinated actions and continuous communication between GACG members. I aim for broader international visibility and tangible results in our anti-counterfeiting efforts.

How does your group plan to increase awareness about the importance of anti-counterfeiting measures among the public and businesses?

Tuomas Kannas: We plan to achieve this by creating and sharing engaging campaigns, reports, and knowledge with relevant stakeholders and the media. It’s also important to mention that the passion our members have for the anti-counterfeiting cause itself plays a pivotal role in driving these efforts.

What kind of technological advancements are you exploring or planning to use to improve IPR enforcement?

Tuomas Kannas: GACG member organizations, their members, and key external stakeholders continually monitor and explore technological advancements in the IPR enforcement landscape. We aim to share this knowledge in the future to improve our collective efforts.

Finally, what programs or initiatives are you most excited about in the coming months or years?

Tuomas Kannas: I’m particularly excited about several upcoming programs, including EMPACT in Europe, the OECD illicit trade group, and programs conducted by the Department of Homeland Security (DHS) and Homeland Security Investigations (HSI). These initiatives hold significant promise in our ongoing battle against counterfeiting.

To learn more about the GACG visit:  https://www.gacg.org/ 

[Helsinki, 30/05/2023] – TrueMed, a leading provider of anti-counterfeiting technology solutions, is pleased to announce the availability of its innovative platform on the SAP Store. This collaboration with SAP, a global leader in enterprise software, marks a significant milestone in the quest for enhanced safety and detailed authentication of pharmaceutical products.

TrueMed’s cutting-edge methods address cases with highly accurate optical detection, surpassing and enhancing the capabilities of standard serialization processes. The advanced technology can be seamlessly integrated into existing business processes and is applicable to both serialized and non-serialized products, providing a comprehensive solution for various scenarios. End-users can easily perform the product authentication with a mobile device.

Jyrki Berg, CEO of TrueMed, expressed his excitement about the partnership, stating, “We are thrilled to offer our innovative product authentication solutions through the SAP Store. This collaboration opens new possibilities for the safety and detailed authentication of pharmaceutical products. By leveraging TrueMed’s advanced AI-technology, businesses can enhance efficiency and ensure superior quality control.”

Florian Heretsch, VP and Head of Mobile Experience & Engineering at SAP, emphasized the potential of the joint SAP/TrueMed offering, stating, “With the addition of TrueMed to the SAP Store, we can introduce a remarkable transformation in the product protection and analysis industry. By integrating AI-based visual authentication and seamlessly merging with current serialization implementations, we can deliver integrated, next-generation solutions that augment SAP’s mobile experience. This partnership empowers our customers to achieve unprecedented levels of safety and accuracy in product authentication.”

TrueMed’s cloud-based SaaS offering is now globally accessible to all SAP customers through the SAP Store. By incorporating TrueMed’s technology into SAP’s comprehensive ecosystem, businesses can drive significant cost savings and enhance efficiency in product authentication and detection processes, without the need for expensive factory processes.

For more information about TrueMed’s advanced track and trace solutions, please visit the SAP Store or contact the TrueMed team directly.

 

About TrueMed.

TrueMed is a leading provider of anti-counterfeiting technology solutions for the life science sector. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing life science companies to quickly and efficiently protect their brands and customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas, TrueMed, tuomas.kannas@truemedinc.com